Park Edge Advisors LLC Buys New Stake in Boston Scientific Corporation $BSX

Park Edge Advisors LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 16,958 shares of the medical equipment provider’s stock, valued at approximately $1,064,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter valued at about $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific during the fourth quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Colonial Trust Co SC raised its stake in shares of Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 231 shares during the last quarter. Finally, Bangor Savings Bank boosted its holdings in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $44.34 on Thursday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 1-year low of $44.05 and a 1-year high of $109.50. The stock has a market capitalization of $65.90 billion, a P/E ratio of 18.55, a P/E/G ratio of 0.87 and a beta of 0.56. The business has a 50-day moving average price of $53.67 and a two-hundred day moving average price of $71.70.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter last year, the firm earned $0.75 EPS. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a share buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on BSX shares. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. Mizuho reduced their price objective on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Oppenheimer set a $90.00 target price on Boston Scientific in a research note on Thursday, April 23rd. Stifel Nicolaus set a $75.00 price target on Boston Scientific in a report on Wednesday, May 27th. Finally, Piper Sandler reiterated an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a research report on Friday, June 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $83.76.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Jefferies kept a Buy rating on Boston Scientific and still sees upside, even after cutting its price target to $67 from $100. Piper Sandler also maintained an Overweight rating, suggesting some analysts remain constructive on the long-term story.
• Positive Sentiment: Analyst coverage continues to frame BSX as oversold with potential upside, which may help support investor confidence if the company can avoid further setbacks.
• Neutral Sentiment: Recent market commentary noted Boston Scientific has been trading well below prior levels, with investors reassessing valuation after the sharp move lower.
• Negative Sentiment: Boston Scientific disclosed a nationwide, firm-initiated recall of Orca Single Use Air/Water and Suction Valves after reports that suction buttons could stick during gastrointestinal endoscopy procedures. The FDA classified the action as a Class II recall, which raises quality-control and regulatory concerns.
• Negative Sentiment: The recall adds to investor worries that even smaller accessory-device issues can hurt operations, increase oversight costs, and pressure sentiment around the company’s medical-device portfolio.
• Negative Sentiment: Options activity also turned more cautious, with unusual buying of put options suggesting some traders are positioning for additional downside in BSX.
• Negative Sentiment: Commentary from Jim Cramer added to the bearish tone, saying the sector is “too hard to own” right now and expressing surprise at the decline in Boston Scientific shares.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.